ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1094

“Lupus Doesn’t Have Me, I Have Lupus” a Patient Centered Quality Improvement Project to Increase Medication Adherence for Patients with Lupus Nephritis

Christopher Macko1, Patty Chen2, Roger Santos3, Nirmala Ramalingam4, Nicole Tran5 and Sijie Zheng6, 1Kaiser Oakland Internal Medicine Residency, Piedmont, CA, 2Kaiser Oakland Medical Center Department of Rheumatology, Orinda, CA, 3Kaiser East Bay Department of Pharmacy, Oakland, CA, 4Kaiser Oakland Medical Center Department of Graduate Medical Education, Oakland, CA, 5Kaiser Oakland Department of Adult and Family Medicine, Oakland, CA, 6Kaiser Oakland Medical Center Department of Nephrology, Oakland, CA

Meeting: ACR Convergence 2023

Keywords: Lupus nephritis, Systemic lupus erythematosus (SLE), Systems-based Studies

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1082–1099) Measures & Measurement of Healthcare Quality Poster I

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Lupus nephritis (LN) is the most common cause of kidney injury in patients with systemic lupus erythematous (SLE) and is associated with higher morbidity and mortality. Low adherence to treatment regimens is common amongst patients with LN and is correlated with high rates of relapse, increased hospitalizations, and poor renal outcomes. Our objective was to assess and identify barriers to medication adherence for our patients with LNon mycophenolate mofetil (MMF).We used this data to design targeted interventions aimed at improving medication adherence for our patients with LN on MMF in our large integrated health system at Kaiser Permanente Oakland Medical Center, California.

Methods: We identified patients with a diagnosis of LN, who were taking MMF between 11/30/21 and 11/30/22. We collected demographic information including age, gender, 30-day copay, ethnicity, requirement of renal replacement therapy, and proportion of days covered (PDC) for MMF. We identified patients with a PDC of less than80% and surveyed them for barriers to medication adherence. Our survey questions sought to elucidate barriers such as medication side effects, cost, refill processes, and lab draws. We also asked open-ended questions to gain insight into how SLE has affected their lives.

Results: Of 37 patients with LNon MMF, almost a third (12/37) had PDC less than 80%. More than half (7/12) of these patients agreed to be interviewed. They identified the following barriers to medication adherence: forgetfulness57% (4/7), incompletelabwork28% (2/7),medication cost 14% (1/7),and intentionally missed doses 14% (1/7). No patients identified medication side effects as a barrier. More than two thirds (5/7) reported no issues with obtaining new prescriptions from the pharmacy. The median 100-day co-pay for MMF was $13.13 and 2/7 (28%) patients paid $0 for their medications.

Conclusion: At KP Oakland, two thirds of our patients with LNare adherent to their MMF; forgetfulness appears to be a challenge for our non-adherent patients. The next steps to our quality improvement initiatives will focus on the following: 1) patient and provider education about tools (medication and lab reminder apps) to promote medication adherence and 2) creating a multidisciplinary rheumatology and nephrology committee to identify and discuss patients with LN who are at risk of disease progression.

Supporting image 1

Abbreviations: RRT- renal replacement therapy, MMF- Mycophenolate Mofetil, LN- Lupus Nephritis

Supporting image 2

Supporting image 3


Disclosures: C. Macko: None; P. Chen: None; R. Santos: None; N. Ramalingam: None; N. Tran: None; S. Zheng: None.

To cite this abstract in AMA style:

Macko C, Chen P, Santos R, Ramalingam N, Tran N, Zheng S. “Lupus Doesn’t Have Me, I Have Lupus” a Patient Centered Quality Improvement Project to Increase Medication Adherence for Patients with Lupus Nephritis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/lupus-doesnt-have-me-i-have-lupus-a-patient-centered-quality-improvement-project-to-increase-medication-adherence-for-patients-with-lupus-nephritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/lupus-doesnt-have-me-i-have-lupus-a-patient-centered-quality-improvement-project-to-increase-medication-adherence-for-patients-with-lupus-nephritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology